达帕格列嗪
恩帕吉菲
医学
2型糖尿病
二甲双胍
血糖性
内科学
糖尿病
不利影响
危险系数
泌尿科
内分泌学
胰岛素
胃肠病学
药理学
置信区间
作者
Eu Jeong Ku,Dong‐Hwa Lee,Hyun Jeong Jeon,Tae Keun Oh
标识
DOI:10.1016/j.diabres.2021.109123
摘要
AimsTo investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor.MethodsA total of 362 patients with T2D were enrolled for this 3-year open-label, prospective observational study. Empagliflozin (25 mg/day, n = 185) or dapagliflozin (10 mg/day, n = 177) was added to the existing triple drug regimen. HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated.ResultsAt 3 years, changes in HbA1c and FPG were −1.7% (standard error [SE] 0.10) and −60.0 mg/dL(2.2), and −1.1%(0.12) and −48.1 mg/dL(3.6), for empagliflozin and dapagliflozin group, respectively (P = 0.001 and P = 0.055). Empagliflozin group showed significantly greater body weight reduction (-4.5 kg [SE 0.35] vs. −1.0 kg [SE 0.40], P = 0.024) and had beneficial effects on HDL cholesterol and LDL cholesterol (both P < 0.05). The overall incidence of adverse events, cardiovascular events and mortality did not differ between the two groups.ConclusionsQuadruple combination therapy with either empagliflozin or dapagliflozin showed a positive long-term effect in the glycemic control and body weight reduction with generally well tolerance. In general, the use of empagliflozin performed better than dapagliflozin.Clinical Trial Number NCT03748810 (ClinicalTrials.gov).
科研通智能强力驱动
Strongly Powered by AbleSci AI